Oncology & Cancer

The role of fibronectin in BRAF-mutant thyroid cancer treatment

New research overseen by University of Colorado Cancer Center member Rebecca Schweppe, Ph.D., could lead to improved treatment for people with thyroid cancer characterized by a mutation in the BRAF gene—a mutation also ...

Oncology & Cancer

Q&A: Treatment for Hurthle cell thyroid cancer

Dear Mayo Clinic: Is it common to only have a partial thyroidectomy to remove Hurthle cells? My doctor is recommending this procedure, but I wonder if I should have my entire thyroid removed instead to eliminate the risk ...

Oncology & Cancer

Wording used may affect thyroid cancer patients' anxiety, choices

(HealthDay)—The terminology used to describe small papillary thyroid cancers (PTCs) may affect patients' anxiety levels and treatment choices, according to a study published online Aug. 23 in JAMA Otolaryngology-Head & ...

Oncology & Cancer

Drop the C-word to reduce anxiety and overtreatment, say experts

Medical researchers are calling for the word 'cancer' to be dropped from some doctor-patient conversations in a bid to reduce patient anxiety and harm from over treatment.The appeal in today's BMJ follows mounting evidence ...

Oncology & Cancer

Pediatric cancer drug shows 93 percent response rate

A first-of-its-kind drug targeting a fused gene found in many types of cancer was effective in 93 percent of pediatric patients tested, researchers at UT Southwestern's Simmons Cancer Center announced.


Lymph node density predicts thyroid cancer outcomes

(HealthDay)—Lymph node density (LND) can help predict outcomes in patients with papillary thyroid cancer, according to a study published online Nov. 30 in JAMA Otolaryngology—Head & Neck Surgery .

page 1 from 4